Loading...
ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma
INTRODUCTION: Omalizumab is a novel anti-IgE therapy for patients having inadequately controlled severe persistent allergic asthma with uncontrolled symptoms despite GINA 2002 step 4 therapy (inhaled ICS + LABA∓ additional controller medication as necessary). Omalizumab reduces exacerbations in thes...
Na minha lista:
| Udgivet i: | Prim Care Respir J |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Nature Publishing Group
2006
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6730752/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.136 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|